By Brian Nichols : In this article, I am looking at four more events in biotechnology that could spark substantial gains during the remainder of this year. Already, I have covered four such events including upcoming data announcements, product launches, and FDA approval decisions. In this second ...
Shares of Intermune ( ITMN +10.2% ) rise after the disclosure of mixed late-stage trial results for Boehringer Ingelheim's rival drug. The company
BANGALORE (Reuters) - Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials.
limited detail to directly compare with InterMune ’s Phase III results, the key takeaway ..... Overall, this does not change our view on InterMune ’s prospects as we were anticipating ..... our market model for Esbriet. While InterMune ’s stock is reacting positively to the
Gainers: ECYT +145% . UPIP +64% . LIN +32% . MNGA +30% . GNK +24% . MEG +15% . EJ +12% . ITMN +10% . OXGN +7% . IPCI +6% . PRAN +5% . Losers: SYMC -10% . ISR -8% . ICLD -8% . PBF -7% . CMGE -6% . ENLK -5% . Post your comment!
InterMune ( ITMN ) prices its offering of 7.5M shares of common stock at $32.75/share netting $233M to the company. Overallotment is 1.125M shares. Proceeds will be used to fund Esbriet commercialization . Post your comment!
Top gainers, as of 5:15 p.m.: FV +19.4% . CALL +16.9% . KKD +11.0% . IBCP +6.5% . WSM +6.2% . Top losers, as of 5:15 p.m.: MDU -9.1% . MLNK -8.0% . MILL -5.6% . ITMN -3.5% . MUX -3.0% . Post your comment!
InterMune ( ITMN ) to offer 7.5M shares of common stock for public sale plus an optional 1.125M shares for underwriters. The company will use
Goldman Sachs upgrades InterMune ( ITMN ) to Buy with a price target of $45 citing better-than-expected top line Phase 3 results for pirfenidone. 11 of 14 analysts
SMSI +44% . SKUL +33% . ATAI +25% . PLUG +23% . BIG +21% . ZOOM +20% . OHRP +17% . SPRO +17% . THTI +17% . ITMN +15% . Top 10 Losers: NVTL -25% . PXLW -20% . ALSK -17% . ALOG -17% . TACT -14% . DPW -14% . BAXS -14% . NMRX